Aevi Genomic Medicine (Aevi Genomic Medicine) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2019)

Aevi Genomic Medicine Capex-to-Operating-Cash-Flow Chart

Aevi Genomic Medicine Annual Data
	Trend	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18
Capex-to-Operating-Cash-Flow		Get a 7-Day Free Trial					-	-	-	-	-

Aevi Genomic Medicine Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Capex-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Aevi Genomic Medicine's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Aevi Genomic Medicine's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aevi Genomic Medicine's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aevi Genomic Medicine's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Aevi Genomic Medicine's Capex-to-Operating-Cash-Flow falls into.

Aevi Genomic Medicine Capex-to-Operating-Cash-Flow Calculation

Aevi Genomic Medicine's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2018 is calculated as

Aevi Genomic Medicine's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2019 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aevi Genomic Medicine  (NAS:GNMX) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.

Aevi Genomic Medicine Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Aevi Genomic Medicine (Aevi Genomic Medicine) Business Description